$OCS News

HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target

Oculis Reports New Phase 2 ACUITY Biomarker Data  Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki

Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

Oculis To Report Topline Results Around Year-End 2026 From First Genotype-Guided Registrational Dry Eye Trial Of Licaminlimab, Now Fully Randomized With 176 Patients, Two-Thirds Carrying Target TNFR1 Variant

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis Announces Resignation of Lionel Carnot from Board of Directors

After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)

HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $39

Oculis Holding AG: Navigating Through Major Trial Setback

Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?

JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $20